Gilead's Covid Drug Gets EU Regulator's Nod for Use on Children
September 16 2022 - 07:46AM
Dow Jones News
By Dean Seal
Gilead Sciences Inc. said Friday that a major European regulator
has recommended the company's Covid-19 treatment, remdesivir, to be
used to treat children.
The Committee for Medicinal Products for Human Use, part of the
European Medicines Agency, adopted the positive opinion that the
indication for remdesivir, sold as Veklury, should be extended to
treat certain pediatric patients, including those who don't require
supplemental oxygen and are at increased risk of progressing to
severe Covid-19. The regulator also recommended that remdesivir be
used to treat those who are least 4 weeks old with SARS-CoV-2 and
pneumonia who do require supplemental oxygen.
The European Commission will now review the recommendation. If
adopted, Veklury would be the only Covid-19 treatment approved for
adolescents at high risk of progressing to a severe form of the
virus and pediatric patients who require supplemental oxygen.
In the European Economic Area, Veklury is the only antiviral
approved to treat adults with Covid-19 who don't require
supplemental oxygen and are at risk of developing a severe form of
the disease, the company said.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
September 16, 2022 07:31 ET (11:31 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jan 2023 to Feb 2023
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Feb 2022 to Feb 2023